Search PubMed⌕ Search

Biomedical subjects

P Serra e Silva

Publications and source records attributed to P Serra e Silva.

6 recordsLinked to original sources
PubMed1998

Does obesity influence ciprofibrate activity?

STUDY OBJECTIVE: The association of obesity and dyslipidemia, namely high triglycerides and low HDL-cholesterol levels, is well known, but, as far as we are aware, the possible influence of obesity on the efficacy of current hypolipidemic drugs has never been studied. Therefore, we investigated the relationship between obesity and ciprofibrate efficacy. METHODS: This was a post-hoc analysis of an open-label study with 6-month therapy of ciprofibrate carried out in the Atherosclerosis Out-Patient Clinic of Coimbra University Hospital. Eligible patients were 30 to 70 years old with cholesterol > 6.2 mmol L-1 and/or triglycerides > 2.23 mmol L-1. A sequential sample of 20 patients was selected but only 18 completed the study. After at least one month of diet or washout period all participants were given 100 mg day-1 of ciprofibrate. Triglycerides, total (TC) and HDL-cholesterol (HDL-C), apoproteins A-1, B100 and (a), and fibrinogen were measured at the beginning and at the end of the study. LDL-cholesterol (LDL-C) was calculated by the Friedewald formula. MAIN RESULTS: Baseline and the percentage of modification with ciprofibrate (delta%) of triglycerides correlated positively with body mass index (BMI) and waist/hip ratio (WHR). Baseline HDL-C correlated negatively with BMI and WHR, but delta% correlated positively with BMI. Fibrinogen behaved differently from triglycerides. The negative correlations between BMI and WHR and the delta% of LDL-C lost power and significance in stepwise regression after the introduction of types of dyslipidemias as an independent variable. CONCLUSIONS: Ciprofibrate may be particularly effective in obese patients with high triglycerides and low HDL-C, a subject deserving further research.

Adult↗
PubMed1995

[Effectiveness of ciprofibrate. Open study in a Portuguese population].

STUDY OBJECTIVE: To determine the efficacy of ciprofibrate in portuguese patients with hypercholesterolaemia, hypertriglyceridaemia and mixed hyperlipidaemia. DESIGN: Open-label study with 6-month therapy. SETTING: Out-patient clinics of two Central Hospitals. PARTICIPANTS: Sequential sample of 40 patients 20 from each hospital. 37 patients (92.5%) completed the study; 14 had dyslipidaemia type IIa, 12 type IIb and 11 type IV. METHODS: After at least one month of diet or washout period, all participants were given 100 mg/day of ciprofibrate, taken after the evening meal. Analysis and clinical examinations were performed at weeks (-4), (0), (+8), (+16) and (+24). Total (TC) and HDL (HDL-C) cholesterol, triglycerides (TG), apoproteins A-I, B100, and (a), and fibrinogen were determined. LDL-cholesterol (LDL-C) was calculated by means of the Friedewald formula, whenever TG < or = 400 mg/dl. MAIN RESULTS: With ciprofibrate, in the whole population, TC, TG, LDL-C, apoB100, and TC/HDL-C ratio diminished, respectively 16.6%, 46.2%, 20.7%, 12.6% and 24.6%. HDL-C and apoA-I increased 10.4% and 4.2%. LDL-C was reduced by 29.5% (p = 0.0001) in type IIa patients, and increased 23% (not statistically significant) in type IV patients. The reduction of TG attained 57.4% in type IIb patients. One type IIb patient received 200 mg/day of the drug from week (+16) on. BMI, waist/hip ratio, hypertension, alcohol consumption and sex didn't affect ciprofibrate activity. CONCLUSIONS: These results confirm the high efficacy of ciprofibrate in patients with hypercholesterolaemia, hypertriglyceridaemia and mixed hyperlipidaemia. In type IIa dyslipidaemia, the reduction of LDL-C was roughly equivalent to that of the less potent statins. In type IV dyslipidaemia LDL-C may increase moderately. The influence on apoprotein (a) and fibrinogen was positive but modest.

Adolescent↗
PubMed1995

[Safety of ciprofibrate. Open study in a Portuguese population].

STUDY OBJECTIVE: To determine the safety of ciprofibrate in portuguese patients with dyslipidaemia. DESIGN: Open-label study with 6-month therapy. PARTICIPANTS: Sequential sample of 40 patients, 20 from each hospital, 37 patients (92.5%) completed the study. METHODS: After at least one month of diet or washout period, all participants were given 100 mg/day of ciprofibrate, taken after the evening meal. Analysis and clinical examinations were performed at weeks (-4), (0), (+8), (+16) and (+24). Glycemia, uric acid, creatine kinase, creatinine and transaminases were determined. MAIN RESULTS: Thirty-seven patients ended the study (92.5%), three abandoned because of gastrointestinal adverse effects, six other patients also complaint of gastrointestinal side effects. The creatinine and creatine kinase levels increased 9.7% and 19.2%, although kept in the normal range. There were no statistically significant changes in glycemia, uric acid and transaminases levels. CONCLUSIONS: These results confirm the high safety of ciprofibrate in patients with dislipidaemia. The short term of this study does not allows taking conclusions about long term use of this drug.

Adolescent↗
PubMedDate not supplied

Experimental atherogenesis and vascular noradrenaline content in NZW rabbits and activity of a new nicotinic acid derivative (L 44-0).

New Zealand White rabbits fed a low-level cholesterol-enriched diet (0.1%) were used to study and characterize a possible model of experimental atherogenesis. For the determination of the degree of atherosclerosis, more consistent and reproducible morphometric methods were used. Simultaneously the influence of plasma cholesterol levels on vascular noradrenaline content was studied. The effect of a new lipid-regulating drug (0.1% L 44-0, the N-oxide of a nicotinic acid derivative) on analyzed parameters was studied as well. This study suggests that the low-level cholesterol-enriched diet is atherogenic, with macroscopically detectable lesions of atherosclerosis becoming apparent by week 12 of the study. The same diet increases the vascular noradrenaline content in the renal artery and in the femoral artery and vein; however, it does not influence that content in the carotid and mesenteric arteries. L 44-0 counteracts most of the observed effects.

Animals↗